NASDAQ:BIAF
bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc.'s revenue fell 34.2% in fiscal 2025 to $6.2M while operating margin fell to −171.6%, its lowest in 4 years. Free cash flow was −$9.4M, −152.4% of revenue, and the diluted share count rose 325.8%.Summary generated from bioAffinity Technologies, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$6.2M
Revenue growth−34.2%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−171.6%
Net margin−242.0%
ROICn/a
Return on equity−301.8%
Debt / equityn/a
Free cash flow−$9.4M
FCF margin−152.4%
Share count change+325.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 7 | 8 | 9 | 6 |
| Operating income | −2 | −4 | −8 | −9 | −11 |
| Net income | −6 | −8 | −8 | −9 | −15 |
| Free cash flow | n/a | −4 | −6 | −7 | −9 |
Recent filings
- 8-KEntry into a material agreement
Oct 9, 2026 - 8-KOther events
Oct 8, 2026 - 8-KOther events
Oct 6, 2026 - 8-KOther events
Sep 30, 2026 - 8-KOther events
Sep 22, 2026 - 8-KOther events
Sep 17, 2026 - 8-KRegulation FD disclosure
Sep 11, 2026 - 8-KOther events
Sep 9, 2026